IN8bio Statistics
Total Valuation
IN8bio has a market cap or net worth of $13.51 million. The enterprise value is -$2.27 million.
| Market Cap | 13.51M |
| Enterprise Value | -2.27M |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
IN8bio has 9.86 million shares outstanding. The number of shares has increased by 405.26% in one year.
| Current Share Class | 9.86M |
| Shares Outstanding | 9.86M |
| Shares Change (YoY) | +405.26% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 3.17% |
| Owned by Institutions (%) | 19.88% |
| Float | 7.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.21, with a Debt / Equity ratio of 0.12.
| Current Ratio | 8.21 |
| Quick Ratio | 7.97 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -111.11% and return on invested capital (ROIC) is -61.70%.
| Return on Equity (ROE) | -111.11% |
| Return on Assets (ROA) | -58.37% |
| Return on Invested Capital (ROIC) | -61.70% |
| Return on Capital Employed (ROCE) | -98.51% |
| Weighted Average Cost of Capital (WACC) | 5.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.04M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.38% in the last 52 weeks. The beta is 0.31, so IN8bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -39.38% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 1.54 |
| Relative Strength Index (RSI) | 65.80 |
| Average Volume (20 Days) | 45,966 |
Short Selling Information
The latest short interest is 63,110, so 0.64% of the outstanding shares have been sold short.
| Short Interest | 63,110 |
| Short Previous Month | 90,842 |
| Short % of Shares Out | 0.64% |
| Short % of Float | 0.88% |
| Short Ratio (days to cover) | 1.48 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.20M |
| Pretax Income | -18.67M |
| Net Income | -18.67M |
| EBITDA | -17.80M |
| EBIT | -19.20M |
| Earnings Per Share (EPS) | -$1.48 |
Balance Sheet
The company has $17.96 million in cash and $2.18 million in debt, with a net cash position of $15.78 million or $1.60 per share.
| Cash & Cash Equivalents | 17.96M |
| Total Debt | 2.18M |
| Net Cash | 15.78M |
| Net Cash Per Share | $1.60 |
| Equity (Book Value) | 18.36M |
| Book Value Per Share | 1.86 |
| Working Capital | 16.24M |
Cash Flow
In the last 12 months, operating cash flow was -$14.36 million and capital expenditures -$242,000, giving a free cash flow of -$14.60 million.
| Operating Cash Flow | -14.36M |
| Capital Expenditures | -242,000 |
| Depreciation & Amortization | 1.40M |
| Net Borrowing | -403,000 |
| Free Cash Flow | -14.60M |
| FCF Per Share | -$1.48 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IN8bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -405.26% |
| Shareholder Yield | -405.26% |
| Earnings Yield | -137.70% |
| FCF Yield | -107.68% |
Analyst Forecast
The average price target for IN8bio is $7.00, which is 410.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 410.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 6, 2025. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jun 6, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |